Payer-focused value Mindera Health offers Mind.Px to determine patient receptivity to expensive psoriasis biologics, enabling payers to save money at the point of prescription. Target payer organizations and PBMs with a value proposition centered on reducing waste and optimizing drug spend.

Strategic partnerships Recent collaborations with the National Psoriasis Foundation and pharmacy benefit managers indicate a channel strategy that can be expanded. Focus on co-marketing with patient advocacy groups and PBMs to broaden adoption and drive payer-backed reimbursement.

Regulatory momentum Mindera Health recently received New York State Department of Health approval for Mind.Px, signaling regulatory progress and potential trust signals for other state-level approvals. Leverage this momentum to approach insurers and large health systems seeking validated diagnostics.

Clinical expansion The Mind.Px platform is positioned as the first test in a broader pipeline for psoriatic arthritis and eczema biologic receptivity. Sales opportunities exist in expanding to related dermatology indications and partnering with dermatology-focused clinics and hospital networks.

Tech-enabled services The technology stack supports scalable data analysis and dermal biomarker testing. Highlight opportunities to collaborate with health systems and digital health platforms that prioritize data-driven precision medicine, enabling integration into existing telemedicine or EHR workflows.